Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

NCT05603143 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

468

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the low number of events.

Conditions

COVID-19

Interventions

DRUG: Obeldesivir
DRUG: Obeldesivir Placebo

Sponsor

Gilead Sciences